Related Experiment Video
Updated: Aug 10, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery
Keyvan Karkouti1, Duminda N Wijeysundera, Terrence M Yau
1Department of Anesthesia, University Health Network, University of Toronto, Toronto, Ontario, Canada. keyvan.karkouti@uhn.on.ca
Insights
Leukoreduced platelet transfusions in cardiac surgery did not show an association with adverse clinical outcomes. This finding holds true even when accounting for significant confounding factors in the analysis.
Area of Science:
- Cardiovascular Surgery
- Transfusion Medicine
- Hematology
Background:
- Cardiac surgery patients often require blood product transfusions.
- The use of leukoreduced platelets aims to mitigate transfusion-related complications.
- Understanding the independent impact of platelet transfusions is crucial for patient safety.
Purpose of the Study:
- To investigate the independent association between leukoreduced platelet transfusions and adverse clinical outcomes.
- To analyze the relationship in the context of cardiac surgery procedures.
Main Methods:
- Observational study with prospectively collected data from 11,459 cardiac surgery patients (1999-2004).
- Multivariable logistic regression and propensity score case-control analyses were employed.
- Evaluated associations between platelet transfusion and outcomes like myocardial infarction, stroke, renal failure, sepsis, and death.
Main Results:
- 19% of patients received leukoreduced platelets.
- While adverse event rates were higher in transfused patients, no statistically significant association was found.
- Neither logistic regression nor propensity score analyses identified a link between platelet transfusion and adverse events.
Conclusions:
- Leukoreduced platelet transfusions in cardiac surgery are not independently associated with adverse clinical outcomes.
- Adjusting for confounders is essential when evaluating transfusion effects.
- Findings support the safety of leukoreduced platelet use in this patient population.
Purpose:
To determine the independent relationship between leukoreduced platelet transfusions and adverse events in cardiac surgery.
Methods:
In this observational study, detailed baseline and perioperative data were prospectively collected on consecutive patients who underwent cardiac surgery at a single institution from 1999 to 2004. The independent associations of platelet transfusion with clinical outcomes (low output syndrome, myocardial infarction, stroke, renal failure, sepsis, and death) were determined by multivariable logistic regression analysis and propensity score case-control analysis.
Results:
Of the 11,459 patients analyzed, 2,174 (19%) received (leukoreduced) platelets - 1,408 received 5 U, 471 received 10 U, 140 received 15 U, and 155 received 20 or more units. Although all measured adverse event rates were higher in those who received platelets, in neither the logistic regression analyses nor the propensity score analyses was there any association between platelet transfusion and any of the adverse events.
Conclusions:
Transfusion of leukoreduced platelets in cardiac surgery is not associated with adverse clinical outcomes when adjustments are made for important confounders.
